Every Form 4 that HCW Biologics Inc. (HCWB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HCWB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCWB filings page.
HCW Biologics Inc. reports that CEO and 10% owner Hing C Wong purchased 23,210 shares of Common Stock at $2.585 per share in a private placement directly from the issuer under a July 29, 2026 Securities Purchase Agreement, bringing his direct holdings to 125,845 shares. Under the same agreement, he is entitled to common warrants exercisable for up to 23,210 additional shares, with issuance subject to stockholder approval under Nasdaq Listing Rule 5635(d); once issued, the warrants will be exercisable immediately and expire 5.5 years after issuance.
HCW Biologics Inc. SVP of Business Development Lee Flowers purchased 7,736 shares of common stock at $2.585 per share on July 29, 2026, increasing his direct holdings to 8,691 shares. The shares were bought directly from the issuer in a private placement under a Securities Purchase Agreement exempt from registration. Flowers is also entitled to receive common warrants exercisable for up to 7,736 additional shares, with issuance subject to stockholder approval under Nasdaq Listing Rule 5635(d); upon issuance, these warrants would be immediately exercisable and expire 5.5 years after issuance.
HCW Biologics director Garrett Scott T, through Garrett Capital Partners, LLC, purchased 7,736 shares of Common Stock at $2.585 per share on July 29, 2026 in a private placement directly from the company under a Securities Purchase Agreement. He will also be entitled to common warrants for up to 7,736 shares, subject to stockholder approval under Nasdaq Listing Rule 5635(d). Following this transaction, his indirect holdings total 41,644 shares.
HCW Biologics Inc. director and Chief Executive Officer Hing C. Wong reported significant personal purchases of the company’s securities. On May 22, he bought 113,879 shares of Common Stock at $1.405 per share and acquired Common Stock Purchase Warrants for another 113,879 underlying shares with a $1.28 exercise price, both directly from the issuer in a private placement. Following these transactions, he directly owns 615,790 shares of Common Stock and 118,110 warrants, increasing his overall economic exposure to the company.
HCW Biologics Inc. director T. Scott Garrett, through an LLC, reported net buying activity in both common shares and warrants. The LLC acquired 177,936 shares of common stock at $1.405 per share in a private placement directly from the issuer, which the footnote states is exempt from Section 16(b) under Rule 16b-3(d). Following this transaction, indirect holdings of common stock rose to 203,441 shares. The LLC also acquired 177,936 Common Stock Purchase Warrants with an exercise price of $1.28 per share, expiring on November 22, 2031, increasing indirect warrant holdings to 180,628. In total, the filing shows 355,872 shares’ worth of net buy-side exposure added across stock and warrants.
HCW Biologics Inc. Chief Financial Officer Rebecca Byam bought additional equity in the company on May 22, 2026. She purchased 14,235 shares of common stock at an average price of $1.405 per share, increasing her direct common stock holdings to 57,245 shares.
Byam also acquired a Common Stock Purchase Warrant for 14,235 underlying shares with a conversion price of $1.28 per share, expiring on November 22, 2031, bringing her directly held warrants to 18,466. According to the filing, these securities were purchased directly from the issuer in a private placement exempt from Section 16(b) under Rule 16b-3(d).